Literature DB >> 33461526

The association of erythropoietin-stimulating agents and increased risk for AV-fistula dysfunction in hemodialysis patients. A retrospective analysis.

Anna Wärme1,2, Henrik Hadimeri3, Salmir Nasic4, Bernd Stegmayr5.   

Abstract

BACKGROUND: Patients in maintenance hemodialysis (HD) need a patent vascular access for optimal treatment. The recommended first choice is a native arteriovenous fistula (AVF). Complications of AVF are frequent and include thrombosis, stenosis and infections leading to worsening of dialysis efficacy. Some known risk factors are age, gender and the presence of diabetes mellitus. The aim was to investigate if further risk variables are associated with dysfunctional AVF.
METHODS: This retrospective observational study included 153 chronic HD patients (Cases) referred to a total of 473 radiological investigations due to clinically suspected complications of their native AVF. Another group of chronic HD patients (n = 52) who had a native AVF but were without history of previous complications for at least 2 years were controls. Statistical analyses included ANOVA, logistic regression, parametric and non-parametric methods such as Student's T-test and Mann-Whitney test.
RESULTS: Among Cases, at least one significant stenosis (> 50% of the lumen) was detected in 348 occasions. Subsequent PTA was performed in 248 (71%). Median erythropoiesis-stimulating agent (ESA) weekly doses were higher in Cases than in Controls (8000 vs 5000 IU, p < 0.001). Cases received higher doses of intravenous iron/week than the Controls before the investigation (median 50 mg vs 25 mg, p = 0.004) and low molecular weight heparin (LMWH, p = 0.028). Compared to Controls, Cases had a lower level of parathyroid hormone (median 25 vs 20 ρmol/L, p = 0.009). In patients with diabetes mellitus, HbA1c was higher among Cases than Controls (50 vs 38 mmol/mol, p < 0.001). Multiple regression analysis revealed significant associations between Cases and female gender, prescription of doxazocin, and doses of ESA and LMWH. There was no difference between the groups regarding hemoglobin, CRP or ferritin.
CONCLUSION: In conclusion, the present study indicated that the factors associated with AVF problems were high doses of ESA, iron administration, and tendency of thromboembolism (indicated by high LMWH doses); the use of doxazocin prescription, however, requires further investigation.

Entities:  

Keywords:  Arterio-venous fistula; Erythropoietin; Hemodialysis; Stenosis

Mesh:

Substances:

Year:  2021        PMID: 33461526      PMCID: PMC7814716          DOI: 10.1186/s12882-020-02209-6

Source DB:  PubMed          Journal:  BMC Nephrol        ISSN: 1471-2369            Impact factor:   2.388


  70 in total

1.  Erythropoietin use in critically ill patients: forest and trees.

Authors:  Howard L Corwin
Journal:  CMAJ       Date:  2007-09-05       Impact factor: 8.262

2.  Factors predicting failure of AV "fistula first" policy in the elderly.

Authors:  Tammy Hod; Ranil N Desilva; Bhanu K Patibandla; Yael Vin; Robert S Brown; Alexander S Goldfarb-Rumyantzev
Journal:  Hemodial Int       Date:  2013-10-28       Impact factor: 1.812

3.  Editor's Choice - Vascular Access: 2018 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS).

Authors:  Jürg Schmidli; Matthias K Widmer; Carlo Basile; Gianmarco de Donato; Maurizio Gallieni; Christopher P Gibbons; Patrick Haage; George Hamilton; Ulf Hedin; Lars Kamper; Miltos K Lazarides; Ben Lindsey; Gaspar Mestres; Marisa Pegoraro; Joy Roy; Carlo Setacci; David Shemesh; Jan H M Tordoir; Magda van Loon; Philippe Kolh; Gert J de Borst; Nabil Chakfe; Sebastian Debus; Rob Hinchliffe; Stavros Kakkos; Igor Koncar; Jes Lindholt; Ross Naylor; Melina Vega de Ceniga; Frank Vermassen; Fabio Verzini; Markus Mohaupt; Jean-Baptiste Ricco; Ramon Roca-Tey
Journal:  Eur J Vasc Endovasc Surg       Date:  2018-05-02       Impact factor: 7.069

4.  Thrombophilia and arteriovenous fistula survival in ESRD.

Authors:  Birgitta Salmela; Jari Hartman; Seija Peltonen; Anders Albäck; Riitta Lassila
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-14       Impact factor: 8.237

5.  Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: a propensity score-matched analysis.

Authors:  Rafael Pérez-García; Javier Varas; Alejandro Cives; Alejandro Martín-Malo; Pedro Aljama; Rosa Ramos; Julio Pascual; Stefano Stuard; Bernard Canaud; José Ignacio Merello
Journal:  Nephrol Dial Transplant       Date:  2018-04-01       Impact factor: 5.992

6.  High doses of erythropoietin stimulating agents may be a risk factor for AV-fistula stenosis.

Authors:  Anna Wärme; Ursula Hadimeri; Henrik Hadimeri; Salmir Nasic; Bernd Stegmayr
Journal:  Clin Hemorheol Microcirc       Date:  2019       Impact factor: 2.375

Review 7.  Vascular access complications in daily dialysis: a systematic review of the literature.

Authors:  S Shurraw; D Zimmerman
Journal:  Minerva Urol Nefrol       Date:  2005-09       Impact factor: 3.720

8.  Do blood pressure levels and other patient characteristics influence native fistula patency?

Authors:  Jeyna Irvinn; Nicola Oldman; Philip Sedgwick; Eric Chemla
Journal:  Semin Dial       Date:  2013-12-10       Impact factor: 3.455

9.  Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients.

Authors:  Manoch Rattanasompattikul; Miklos Z Molnar; Joshua J Zaritsky; Parta Hatamizadeh; Jennie Jing; Keith C Norris; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2012-10-08       Impact factor: 5.992

10.  Predictive parameters of arteriovenous fistula functional maturation in a population of patients with end-stage renal disease.

Authors:  Khalid Bashar; Adeel Zafar; Sawsan Elsheikh; Donagh A Healy; Mary Clarke-Moloney; Liam Casserly; Paul E Burke; Eamon G Kavanagh; Stewart R Walsh
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

View more
  2 in total

1.  Heme Oxygenase 1/Peroxisome Proliferator-Activated Receptor Gamma Pathway Protects Intimal Hyperplasia and Mitigates Arteriovenous Fistula Dysfunction by Regulating Oxidative Stress and Inflammatory Response.

Authors:  Tingfei Xie; Yunpeng Xu; Lecai Ji; Xiaolu Sui; Aisha Zhang; Yanzi Zhang; Jihong Chen
Journal:  Cardiovasc Ther       Date:  2022-06-12       Impact factor: 3.368

2.  Contact Laxative Use and the Risk of Arteriovenous Fistula Maturation Failure in Patients Undergoing Hemodialysis: A Multi-Center Cohort Study.

Authors:  Trung Hoang Anh; Phung-Anh Nguyen; Anh Duong; I-Jen Chiu; Chu-Lin Chou; Yu-Chen Ko; Tzu-Hao Chang; Chih-Wei Huang; Mai-Szu Wu; Chia-Te Liao; Yung-Ho Hsu
Journal:  Int J Environ Res Public Health       Date:  2022-06-03       Impact factor: 4.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.